Company intelligence / Profile preview

深圳康泰生物制品股份有限公司 (Shenzhen Kangtai Biological Products Co., Ltd.)

深圳市, 广东省, 中国biokangtai.com ↗

Ownership: Private
Employees: ~1900
Development stage: Commercial

Overview

康泰生物是中国领先的人用创新型疫苗企业，拥有11种上市及获批产品，30余项在研项目。其13价肺炎球菌多糖结合疫苗已实现海外出口，并有新冠灭活及腺病毒载体两款COVID‑19 疫苗获应急使用授权。冻干人用狂犬病（二倍体细胞）等新品种也已获批上市。公司持续推进国际化战略，与全球知名药企合作并积极拓展“一带一路”沿线国家市场。

Therapeutic areas: Infectious Diseases
Modalities: 疫苗（包括病毒减毒活疫苗、病毒灭活疫苗、基因工程疫苗、多价细菌多糖结合疫苗、联合疫苗、病毒载体疫苗、mRNA 疫苗、重组蛋白疫苗等）
Industry: Biotech

Drug pipeline

4 assets

Recombinant hepatitis B vaccine

Commercial

Indications: Hepatitis B

3 more assets in the full pipeline.

Request access →

Partnerships

与默克(Merck)赛诺菲巴斯德(Sanofi Pasteur)荷兰INTRAVACC阿斯利康(AstraZeneca)有技术转移与合作与印尼、巴基斯坦、印度和埃及等“一带一路”国家开展成品出口或技术转移合作。

Beyond the preview

Go deeper on 深圳康泰生物制品股份有限公司 (Shenzhen Kangtai Biological Products Co., Ltd.).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 深圳康泰生物制品股份有限公司 (Shenzhen Kangtai Biological Products Co., Ltd.).

Explore the full profile